{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:01:26Z","timestamp":1648774886148},"reference-count":33,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jns.2014.12.034","type":"journal-article","created":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T01:31:31Z","timestamp":1420248691000},"page":"239-242","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumefactive multiple sclerosis and hepatitis C virus 2a\/2C infection: Dual benefit of long-term interferon beta-1a therapy?"],"prefix":"10.1016","volume":"349","author":[{"suffix":"Jr.","given":"Edward C.","family":"Mader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Richeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin Maury","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lacey L.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo N.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus F.","family":"Lovera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2014.12.034_bb0005","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2014.12.034_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1941874412466873","article-title":"Fulminant demyelinating diseases","volume":"3","author":"Rahmlow","year":"2013","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jns.2014.12.034_bb0015","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archneur.62.11.1673","article-title":"Acute disseminated encephalomyelitis: an update","volume":"62","author":"Menge","year":"2005","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.jns.2014.12.034_bb0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"issue":"16 Suppl. 2","key":"10.1016\/j.jns.2014.12.034_bb0025","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/01.wnl.0000259404.51352.7f","article-title":"Acute disseminated encephalomyelitis","volume":"68","author":"Tenembaum","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.12.034_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1600-0404.1992.tb05490.x","article-title":"Acute demyelinating disease: classification and non-invasive diagnosis","volume":"86","author":"Poser","year":"1992","journal-title":"Neurol Scand"},{"key":"10.1016\/j.jns.2014.12.034_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clineuro.2004.02.016","article-title":"Non-MS recurrent demyelinating diseases","volume":"106","author":"Brinar","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jns.2014.12.034_bb0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410330105","article-title":"Large focal tumor-like lesions of the brain: intermediate between multiple sclerosis and acute encephalomyelitis: a study of 31 patients","volume":"33","author":"Kepes","year":"1993","journal-title":"Ann Neurol"},{"issue":"Pt 7","key":"10.1016\/j.jns.2014.12.034_bb0045","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awn098","article-title":"Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis","volume":"131","author":"Lucchinetti","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jns.2014.12.034_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0889-857X(05)70013-2","article-title":"Hepatitis C-associated autoimmune disorders","volume":"24","author":"McMurray","year":"1998","journal-title":"Clin Rheum Dis Clin North Am"},{"issue":"10","key":"10.1016\/j.jns.2014.12.034_bb0055","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/archneur.58.10.1679","article-title":"Acute disseminated encephalomyelitis associated with hepatitis C virus infection","volume":"58","author":"Sacconi","year":"2001","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.jns.2014.12.034_bb0060","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3349\/ymj.2012.53.4.856","article-title":"A case of acute disseminated encephalomyelitis associated with hepatitis C virus infection","volume":"53","author":"Sim","year":"2012","journal-title":"Yonsei Med J"},{"issue":"3","key":"10.1016\/j.jns.2014.12.034_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/NRL.0b013e31815fa594","article-title":"Neurologic complications of hepatitis C","volume":"14","author":"Acharya","year":"2008","journal-title":"Neurologist"},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2014.12.034_bb0070","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1097\/01.aids.0000192081.33938.2f","article-title":"Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications","volume":"19","author":"Cacoub","year":"2005","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jns.2014.12.034_bb0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-009-0178-z","article-title":"The pathological spectrum of CNS inflammatory demyelinating diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Semin Immunopathol"},{"issue":"9","key":"10.1016\/j.jns.2014.12.034_bb0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3949\/ccjm.77a.09162","article-title":"Hepatitis C virus: prevention, screening, and interpretation of assays","volume":"77","author":"Albeldawi","year":"2010","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"10.1016\/j.jns.2014.12.034_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00005-013-0257-7","article-title":"Seronegative hepatitis C virus infection","volume":"62","author":"Ka\u017amierczak","year":"2014","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"44","key":"10.1016\/j.jns.2014.12.034_bb0090","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.3748\/wjg.v19.i44.7896","article-title":"An insight into the diagnosis and pathogenesis of hepatitis C virus infection","volume":"19","author":"Irshad","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jns.2014.12.034_bb0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223-235.2000","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"24","key":"10.1016\/j.jns.2014.12.034_bb0100","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.3748\/wjg.v20.i24.7555","article-title":"Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview","volume":"20","author":"El-Shamy","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jns.2014.12.034_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Sy","year":"2006","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jns.2014.12.034_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1365-2559.2001.01208.x","article-title":"Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3","volume":"39","author":"Rubbia-Brandt","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.jns.2014.12.034_bb0115","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.21826","article-title":"Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study","volume":"46","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jns.2014.12.034_bb0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jns.2014.12.034_bb0125","first-page":"192","article-title":"Viral genotype and HLA class II alleles influence on extra-hepatic manifestations of chronic HCV infection","volume":"60","author":"Giannitti","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.jns.2014.12.034_bb0130","author":"American Association for the Study of Liver Disease"},{"issue":"6","key":"10.1016\/j.jns.2014.12.034_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1034\/j.1600-0676.2000.020006437.x","article-title":"A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C","volume":"20","author":"Habersetzer","year":"2000","journal-title":"Liver"},{"issue":"5","key":"10.1016\/j.jns.2014.12.034_bb0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2893.2004.00514.x","article-title":"Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients","volume":"11","author":"Cheng","year":"2004","journal-title":"J Viral Hepat"},{"issue":"29","key":"10.1016\/j.jns.2014.12.034_bb0145","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3748\/wjg.v11.i29.4484","article-title":"Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C","volume":"11","author":"Pellicano","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"48","key":"10.1016\/j.jns.2014.12.034_bb0150","first-page":"1686","article-title":"Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection","volume":"49","author":"Tan","year":"2002","journal-title":"Hepatogastroenterology"},{"issue":"8","key":"10.1016\/j.jns.2014.12.034_bb0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jiac.2014.04.009","article-title":"Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C","volume":"20","author":"Nomura","year":"2014","journal-title":"J Infect Chemother"},{"issue":"31","key":"10.1016\/j.jns.2014.12.034_bb0160","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3748\/wjg.v13.i31.4224","article-title":"Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates","volume":"13","author":"Wietzke-Braun","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.jns.2014.12.034_bb0165","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1128\/JVI.78.11.5867-5874.2004","article-title":"Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C","volume":"78","author":"Pham","year":"2004","journal-title":"J Virol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14007990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14007990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T14:51:38Z","timestamp":1537973498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14007990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":33,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0022510X14007990"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.12.034","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumefactive multiple sclerosis and hepatitis C virus 2a\/2C infection: Dual benefit of long-term interferon beta-1a therapy?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}